Polyrizon initiates key usability study program for NASARIX

Polyrizon (PLRZ) announced the initiation of a key usability study program for its lead product candidate, NASARIX, an intranasal allergy blocker designed for broad consumer use. The study marks an important value-inflection milestone in Polyrizon’s development roadmap and is being conducted to confirm alignment with U.S. Food and Drug Administration requirements for critical product elements, including labeling, instructions for use, and overall user interaction. Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development. Successful completion of the usability program will potentially provide essential regulatory evidence supporting NASARIX readiness for clinical evaluation. This milestone represents an important step toward the planned initiation of Polyrizon’s clinical trials, which are expected to commence in Q3 2026, positioning the company for continued advancement along its regulatory and potential commercialization strategy.